AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected in the first quarter of 2025. Enhertu has also earlier received the FDA’s Breakthrough ...

The FDA has approved AstraZeneca and Daiichi Sankyo's Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that was once lumped under the HER2-negative ...

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

Since its initial FDA approval in 2019, Enhertu has repeatedly made history. Its achievements include pioneering the HER2-low breast cancer category and a recent FDA go-ahead in HER2-ultralow disease.

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...